NCT01365312

Brief Summary

Appropriate delivery of adequate nutrition and medications in premature infants often requires central venous access in the form of a special IV called a PICC (peripherally inserted central catheter). While a necessary feature of neonatal intensive care, PICCs pose significant risk: among the most serious of these is infection. One common, successful infection control practice used in older children and adults involves the use of a lock, in which a fluid-filled syringe is attached to the end of an IV when it is not in use in order to prevent and/or treat clotting or infection. The solution is left for some period of time and is then either withdrawn from the line or flushed into the patient. The solution could be saline, antibiotics, other antiseptics, or any combination of these. However in the premature infant, use of antibiotics as a locking compound risks leaving behind organisms resistant to treatment; antiseptics can irritate vessels and cause breakage to sensitive premature skin; saline has neither sterilization nor anti-infective properties. By contrast, ethanol neutralizes or kills most bacteria, viruses, and fungi without the risk of resistance, and because it is not externally applied there is no risk to baby skin. Ethanol-based lock protocols have been used safely and effectively in both adult and pediatric populations without adverse effects, but this has not been tested in premature babies because fluids and medication are delivered continuously: placement of a lock traditionally requires an extended pause (hours or days) in fluid and medication administration. To overcome these key limitations, a periodic, brief ethanol lock protocol was designed such that both infant exposure and interruptions to fluid and medication delivery would be minimized. The lock is practical, cheap, easy to place, and takes advantage of an existing daily pause during which IV tubing and fluids hooked up to the PICC are changed. The objective of this study is to test the hypothesis that use of a 70% ethanol lock, every 3rd day, for 15 minutes, will safely and effectively reduce PICC infection in our unit.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

May 31, 2011

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 3, 2011

Completed
Last Updated

October 3, 2014

Status Verified

October 1, 2014

Enrollment Period

1.3 years

First QC Date

May 31, 2011

Last Update Submit

October 2, 2014

Conditions

Keywords

Central line associated infectionPICC associated infectionNeonatal central line associated sepsisCentral line colonizationEthanol Lock

Outcome Measures

Primary Outcomes (1)

  • Incidence of PICC-related sepsis in infants with ethanol-treated vs. Placebo treated lines

    Primary endpoint of the study is to compare the incidence of PICC-related sepsis in infants with ethanol treated vs. Placebo treated lines by study day 28. PICC-related sepsis is defined by any 2 clinical signs or symptoms plus one positive peripheral blood culture for a recognized pathogen in this population other than coagulase-negative staphylococcus, or 2 positive peripheral blood cultures for coagulase-negative staphylococcus within 48 hours.

    Study Day #28 or sooner if PICC is discontinued before day #28

Secondary Outcomes (6)

  • Evaluation of PICC colonization following ethanol locking

    Duration of PICC use, average of 3 weeks

  • Whether the primary and secondary endpoints differ by birthweight strata

    Duration of PICC use, average of 3 weeks

  • To determine whether ethanol lock treatment impacts incidence of clinical evaluations for suspected sepsis

    Duration of PICC use, average of 3 weeks

  • To determine whether antibiotic use for any indication (including non-bacteremia) alters the incidence of PICC-related infection or colonization as defined in the primary and secondary endpoints

    Duration of PICC use, average of 3 weeks

  • Determine side effects of ethanol locking in premature babies

    Duration of PICC use, average of 3 weeks

  • +1 more secondary outcomes

Study Arms (2)

Ethanol

EXPERIMENTAL

Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.

Drug: Ethanol lock

Heparinized saline

PLACEBO COMPARATOR

Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.

Drug: Heparinized saline

Interventions

Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention

Ethanol

0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo

Heparinized saline

Eligibility Criteria

AgeUp to 32 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Preterm infants \< 32 weeks gestation at birth who require a PICC

You may not qualify if:

  • Any baby with a positive blood culture less than 48 hours prior to PICC placement; any infant who requires pressors in excess of \>5 mcg/kg/min

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

East Carolina University

Greenville, North Carolina, 27834, United States

Location

MeSH Terms

Conditions

Catheter-Related InfectionsBacteremiaSepsis

Condition Hierarchy (Ancestors)

InfectionsBacterial InfectionsBacterial Infections and MycosesSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Amber Fort, DO, MPH, MS

Study Record Dates

First Submitted

May 31, 2011

First Posted

June 3, 2011

Study Start

February 1, 2010

Primary Completion

June 1, 2011

Last Updated

October 3, 2014

Record last verified: 2014-10

Locations